Drug Ming Juno, a leader in cell immunotherapy, is listed on the main board of the Hong Kong Stock Exchange

, an innovative cell immunotherapy company in China's leading clinical phase, today announced the listing of the main board of the Stock Exchange of Hong Kong ("HKEx"). The company focuses on the development, manufacture and commercialization of breakthrough cell immunotherapy for blood and solid tumors.“ The listing in Hong Kong is a very important milestone for pharmaceutical company Ming-Juno. Dr. Yiping Li, Co-Founder, Chairman and CEO of Pharmaceuticals, said, "Pharmaceuticals was founded to change the way cancer patients are treated in China through the development of breakthrough cell therapies. Relying on our state-of-the-art technology platform and research and development capabilities, we will continue to invest in promoting the full commercialization of the core candidates, advancing and expanding our product lines, and continuously enhancing our production capacity and supply chain through innovation and economies of scale., co-founded in 2016 by Juno Therapeutics and Drug Mingkangs, has been a leader in cell immunotherapy, representing the transformation of cancer treatment and the latest breakthrough. Cell immunotherapy, including the embedded antigen-treated T-cell immunotherapy ("CAR-T"), is an innovative treatment that uses human immune cells to fight cancer and is transformative in the field of cancer therapy. Several clinical studies have shown that cell immunotherapy is expected to provide lasting relief to B-cell lymphoma and leukemia, which are difficult to treat by traditional means.The company has established a comprehensive and differentiated pipeline of cell therapy products covering blood and solid tumors. The leading lead product, Relma-cel, is a CD19 target CAR-T therapy for third-line treatments for relapsed or hard-to-treat ("r/r") B-cell lymphoma. China's State Drug Administration ("NMPA") has accepted applications in June 2020 to review the use of relma-cel as a third-line therapy for diffuse large B-cell lymphoma ("DLBCL"), and in September 2020 granted priority examination of new drug applications. In addition, NMPA has awarded relma-cel a breakthrough therapy for the treatment of fyring lymphoma. Relma-cel is expected to become the first CAR-T therapy approved in China for a class of biological products.In addition to being a leader in the field of blood tumor therapy, the use of integrated cell therapy technology platform to enter the real tumor market is also an important part of the future development strategy of Pharmaceuticals. The company has been granted the right to introduce the ARTEMIS® platform from Eureka Technologies, and through a partnership agreement with Lyell Immunopharma ("Lyell"), Pharma plans to combine Lyell's technology with the ARTEMIS® platform to develop a new generation of innard cell therapy for hepatocellular carcinoma ("HCC") therapy.No CAR-T products have yet been approved in China, but according to Frost and Sullivan, the size of China's CAR-T treatment market is expected to grow to Rmb24.3bn by 2030 as potential new products are introduced. Market drivers include an increase in the number of cancer patients, increased drug affordability, and a good regulatory environment.

about the drug ming-Drug Ming Juno is a leading clinical and preclinical cell therapy company in China, founded by U.S.-based Jumbo and Pharmaceutical Mingkangde. The company has established an integrated platform dedicated to the development, manufacture and commercialization of breakthrough cell immunotherapy for blood and solid tumors.The company is committed to developing innovative cell therapist methods for the Chinese market and changing the way cancer is treated in Chinese patients. The company has established a comprehensive and differentiated pipeline of cell therapy products covering blood and solid tumors. The main product, Relma-cel, is an anti-CD19 CAR-T therapy for recurring or incurable ("r/r") B-cell lymphoma, and is expected to become the first CAR-T therapy approved in China for a class of biological products. (Corporate website)